As shown in Figure 5A, treatment with FA-TLR7-1A nearly doubled the ratio of M1:M2 macrophages (as measured by the iNOS:arginase 1 ratio) and halved the percentage of MDSCs in the live CD45+ tumor cell population (Figure 5C). This evidence concerns the gene PTPRC and neoplasm.